Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis : systematic review and economic evaluation
MetadataShow full item record
Melendez-Torres , G J , Auguste , P , Armoiry , X , Maheswaran , H , Court , R , Madan , J , Kan , A , Lin , S , Counsell , C , Patterson , J , Rodrigues , J , Ciccarelli , O , Fraser , H & Clarke , A 2017 , ' Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis : systematic review and economic evaluation ' Health Technology Assessment , vol. 21 , no. 52 , pp. 1-352 . DOI: 10.3310/hta21520
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Melendez-Torres et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. Permission to reproduce material from a published report is covered by the UK government’s non-commercial licence for public sector information.